中生制药(01177.HK)投资於研发生产新冠疫苗企业 涉资5.15亿美元
中生制药(01177.HK)公布,集团全资附属公司香港俊领有限公司就以5.15亿美元向北京科兴中维生物技术有限公司出资立协议。於出资完成後,中生制药将於科兴中维的注册资本中拥有15.03%权益。科兴中维将於中生制药的财务报表中入账列为联营公司。
科兴中维主要从事人用疫苗的研发业务,在新型冠状病毒肺炎疫苗CoronaVac的开发取得了重大进展,是目前中国为数不多自行研发生产新冠疫苗的企业之一。於2020年4月13日,CoronaVac正式获得中国国家药品监督管理局批准进行临床研究,随後又获得了巴西、印尼、土耳其及智利等国家的三期临床试验许可。目前,科兴中维已获得多国的疫苗订单。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.